ArticlePloS one2026
Utilizing the transformer mechanism to predict cervical lymph node metastasis in patients with papillary thyroid carcinoma.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RATIONALE AND
objectiveThe status of cervical lymph node metastasis(LNM) in Papillary thyroid carcinoma(PTC) can affect the patient's treatment plan and prognosis. This study aims to develop and validate the application value of Vision transformer (ViT) model in preoperatively predicting cervical LNM in PTC. MATERIALS AND
methodsA total of 540 PTC patients were retrospectively reviewed from two hospitals from April 20,2022 to August 20,2023.The ViT model is built based on the two-dimensional rectangular ultrasound image of the primary thyroid tumor, and at the same time, to compare its performance, a deep learning model of the traditional Convolutional neural network (CNN) framework, a ultrasound radiomics combined model(Clinical-Rad model), and clinical model are built.
resultsThe ViT model demonstrated an AUC of 0.807 (95% CI: 0.709-0.905) in the internal validation cohort and 0.809 (95% CI: 0.720-0.900) in the external validation cohort. The ViT model's AUC ranged from 0.807-0.814 across all cohorts, significantly exceeding the clinical model (AUC: 0.595-0.669, P<0.001). While the AUC of the ViT model in the training cohort was slightly lower than that of the combined ultrasound radiomics model (0.814 vs 0.828, P=0.491), it showed significantly higher AUC values in the internal (0.807 vs 0.718, P=0.049) and external validation cohorts (0.809 vs 0.691, P<0.001). Compared to the clinical and combined radiomics models, the ViT model exhibited stable and superior predictive performance for PTC cervical lymph node metastasis.In the internal validation cohort, Doctor C's net reclassification improvement (NRI) with the ViT model was 0.106 (P=0.022), and the integrated discrimination improvement (IDI) was 0.106 (P=0.023). Doctor D showed NRI and IDI values of 0.113 (P=0.022) and 0.106 (P=0.024), respectively. In the external validation cohort, Doctor C's NRI and IDI were 0.090 (P=0.024) and 0.106 (P=0.024), while Doctor D had values of 0.011 (P=0.013) and 0.106 (P=0.013). The ViT model enhanced the diagnostic capabilities of both Doctor C, with less clinical experience, and Doctor D, with extensive experience.
conclusionThe deep learning model based on the Transformer mechanism shows good performance in predicting LNM in PTC patients, which is superior to the clinical model, Clinical-Rad model, and traditional CNN model.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.